Activating mutations in oncogenes such as KRAS, BRAF and PIK3CA have been reported in GC through single‐gene analysis at least three decades ago [18, 19, 20, 21] and remain important in GC using genome‐wide strategies [22, 23, 24]. This evidence concerns the gene BRAF and gastric cancer.